Stay updated on GSK2636771 Combo with Pembrolizumab in Melanoma Clinical Trial
Sign up to get notified when there's something new on the GSK2636771 Combo with Pembrolizumab in Melanoma Clinical Trial page.

Latest updates to the GSK2636771 Combo with Pembrolizumab in Melanoma Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedThe page revision/version indicator was updated from v3.5.2 to v3.5.3 for the ClinicalTrials.gov record history interface.SummaryDifference0.1%

- Check18 days agoChange DetectedAdded Revision: v3.5.2 and removed Revision: v3.5.0 from the history page.SummaryDifference0.1%

- Check26 days agoNo Change Detected
- Check47 days agoChange DetectedThe page history now includes a new revision labeled v3.5.0 and removes the previous v3.4.3 entry.SummaryDifference0.1%

- Check62 days agoChange DetectedAdded revision v3.4.3 to the record history and removed revision v3.4.2.SummaryDifference0.1%

- Check83 days agoChange DetectedA new revision entry v3.4.2 was added and the previous revision v3.4.1 was removed in the page history. This is a metadata update to the history log and does not affect study data or page functionality.SummaryDifference0.1%

- Check91 days agoChange DetectedRevision metadata updated: 'Revision: v3.4.1' was added and 'Revision: v3.4.0' was removed. This change affects only page revision information and does not modify study data or navigation. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to GSK2636771 Combo with Pembrolizumab in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the GSK2636771 Combo with Pembrolizumab in Melanoma Clinical Trial page.